ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Thousands of samples already processed

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on May 01, 2021 7:51pm

156 Views

Post# 33109460

RE:RE:Thousands of samples already processed

This form of testing is particularly useful when working with people in custody, according to Tish Trevelyan, a licensed practical nurse with at Correctional Health Services who collected samples for the study. “There were several people in our correctional centres who volunteered to be in the study and happily gave a finger sample, but when it came time for venipuncture, they became extremely anxious due to a fear of needles. We also had some who either had veins that were hard to find due to drug use, or some that found it to be a trigger for them. This really shows how much more accessible the finger is. This method was quick, simple, and most importantly, not too uncomfortable for participants.”

Dry blood-spot testing is also easier from a logistical point of view. All participants’ droplets are pressed onto a card and are fully dried, meaning they can be sealed and safely transported, even in the mail. The samples are then rehydrated in a lab and tested for antibodies.

The data being generated from this study will help to validate COVID-19 serology assays, or antibody presence, used in the BCCDC Public Health Lab. It will also support the roll out of dried blood spot testing for future COVID-19 antibody studies in many settings across the province, and will help with monitoring the efficacy of COVID-19 vaccines.

Mole101 wrote:

That dried test looks familiar ...

https://www.bccdc.ca/about/news-stories/stories/2021/covid-19-antibody-testing-at-bc-corrections

Gbathat wrote: The BC Neuroimmunology Laboratory assay is nearly 100% specific and 100% sensitive with a validation study and all platform comparison with 135 blinded samples. To date, the test is being used for research with BCCDC and the Canada COVID task force on thousands of samples.

https://covidimmunitypassport.com/covid-19-antibodies-test-kits/#1618939695725-312838cd-35ec